Skip to main content
Breast Cancer
For Patients with PIK3CA Mutation–Positive Advanced Breast Cancer, Treatment with Alpelisib plus Fulvestrant May Be Beneficial
Read More
Breast Cancer
Perspectives on Balancing Toxicity and Efficacy When Managing Advanced HER2-Negative Breast Cancer with First-Line Treatment
Read More
Breast Cancer, CDK4/6 Inhibitors
Efficacy Study of Everolimus and Exemestane for the Treatment of Patients with Metastatic Hormone Receptor–Positive Breast Cancer Previously Treated with CDK4/6 Inhibitors
Read More
Breast Cancer, CDK4/6 Inhibitors, Radiation Therapy
Effect of Concomitant Treatment with Radiation Therapy and CDK4/6 in Patients with Advanced Breast Cancer
Read More
Breast Cancer, CDK4/6 Inhibitors
Recent Phase 2 Results for Lerociclib (G1T38), an Oral CDK4/6 Inhibitor Combined with Fulvestrant Used to Treat Patients with Advanced Breast Cancer
Read More
Breast Cancer
Management Strategies for Abemaciclib-Associated Diarrhea in Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
Read More
Breast Cancer
Benefit of Alpelisib When Combined with Fulvestrant as Demonstrated Through Biomarker Subanalysis from the SOLAR-1 Study
Read More
Breast Cancer
Overall Survival Benefit with Ribociclib plus Endocrine Therapy in Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer: 4-Year Follow-Up Study of MONALEESA-7
Read More
Breast Cancer
BYLieve Study Results Support the Use of Alpelisib Combined with Fulvestrant for Hormone Receptor–Positive, HER2-Negative, PIK3CA Mutation–Positive Advanced Breast Cancer
Read More
Breast Cancer
PALOMA-3 Trial Shows Benefits to Overall Survival as Measured by Prognostic Indicators
Read More
Page 107 of 200
Results 1061 - 1070 of 1993